Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Several other equities ...

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today tha This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SEC Filings provided by EDGAR Online, Inc.

Check the time stamp on this data. Updated AI-Generated Signals for Emergent Biosolutions Inc. (EBS) available here: EBS. Type a few symbols and Take a Trial. The signals for these will appear ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

* EPS estimates are Normalized unless otherwise noted.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...